Rylaze
Payments companies reported to CMS as associated with Rylaze. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rylaze, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rylaze
These are the largest totals companies reported as associated with Rylaze. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Dana Salzberg | Phoenix, AZ | Pediatric Hematology-Oncology | $301,399.02 |
| Guillermo Deangulo | Miami, FL | Pediatric Hematology-Oncology | $166,100.11 |
| Luke Maese | Salt Lake City, UT | Pediatric Hematology-Oncology | $158,987.15 |
| Scott Howard | Memphis, TN | Pediatric Hematology-Oncology | $149,987.73 |
| Lauren Huang | Seattle, WA | Pediatrics (Nurse Practitioner) | $141,650.05 |
| Stanton Goldman | Dallas, TX | Pediatric Hematology-Oncology | $125,848.06 |
| Haydar Frangoul | Nashville, TN | Pediatric Hematology-Oncology | $111,768.51 |
| Mitchell Cairo | Hawthorne, NY | Pediatric Hematology-Oncology | $91,243.52 |
| Rebecca Johnson | Tacoma, WA | Pediatric Hematology-Oncology | $80,776.74 |
| Julie Asch | Salt Lake City, UT | Pediatric Hematology-Oncology | $57,713.79 |
Prescribed Rylaze?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.